Morphoceuticals focuses on understanding and manipulating the bioelectrome to induce regeneration and treat disease.

Morphoceuticals

Morphoceuticals is a new biotech company creating the first map of the druggable bioelectrome. By using multi-omics, bioelectric profiling and AI, we aim to exploit the electrical network controlling tissue repair and organ regeneration that exists throughout our bodies.

Our CEO, James Jenson, caught up with Danny Sullivan at Longevity.Technology to talk about our progress toward building the first map of the druggable bioelectrome. Check it out here.

We are excited to welcome James Jenson, PhD as our CEO! With more than 35 years of experience in the biotech and pharmaceutical industries, as both an entrepreneur and executive leader, Jim joins our growing team as we build the first map of the druggable bioelectrome.
	
The ‘bioelectrome’ refers to electrical networks throughout the body, powered by ions rather than electrons as in metal wires. These electrical networks are the cognitive glue that binds multi-cellular collectives together to a common purpose, processing information that controls tissue repair and organ regeneration.

Read more here: https://bit.ly/3W4QGP4

David Kaplan, one of the founders of Morphoceuticals has been named a Fellow of the National Academy of Inventors.

MORP

COM:MORPHOCEUTICALS

Morphoceuticals

locale

market

industry

website

linkedin

founding date

investor of

Metrics